leisure time -WSS

leisure time

author：knowledge 2025-10-02 22:28:03 - browse：255

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

WSS

Prime Medicine, Myeloid Therapeutics clash over genome

Unique patient identifier: Experts argue the benefits, pitfalls

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Updated Covid vaccine has 54% effectiveness, new study suggests

What’s missing from the debate over nursing home staff minimums

Devoted Health’s losses in Medicare Advantage persist

entertainment

leisure time

hotspot

How one medical school became remarkably diverse

Gene therapy for Afghan refugees’ infant will be fully covered

Virginia high school admissions case could be legal follow

SEC charges former device maker CEO with $41 million fraud

Heart attack and stroke risk calculators need revising

Johnson & Johnson sued for allegedly overpaying for workers' drugs

After affirmative action ruling, medical educators look to 'holistic review'

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Tori Bowie and the unacceptable rates of Black maternal death

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

hotspot

Global cancer cases to surge 77% by 2050, WHO report says

Drinking less cuts risk of oral cavity, esophageal cancer: Report

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

SEC charges former device maker CEO with $41 million fraud

What’s missing from the debate over nursing home staff minimums

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Wikipedia

knowledge

explore

leisure time